Significant correlations of sLRPl with biomarkers and clinical variables at enrollment and 6 months after enrollment.
| Enrollment Visit, n = 96 | 6-month Visit, n = 58 | |||
|---|---|---|---|---|
| Median (IQR) | r (P) | Median (IQR) | r (P) | |
| Age, yrs | 10.0 (6.0–14.0) | -0.309 (0.002) | 9.8 (5.0–14.3) | -0.324 (0.01) |
| No. active joints | 5.0 (2.0–12.0) | –0.235 (0.02) | 1.0 (0.0–3.0) | |
| IFN-aa | 27.1 (16.0–46.9) | 0.443 (0.001) | 29.1 (19.2–45.8) | 0.359 (0.006) |
| IFN-yb | 7.0 (4.0–15.2) | 0.335 (0.001) | 7.0 (4.0–15.2) | |
| IL-10c | 7.1 (1.8–16.2) | 0.315 (0.005) | 6.5 (3.3–14.2) | |
| IL-12p40c | 22.7 (9.4–47.9) | 0.428 (0.001) | 7.1 (1.8–16.2) | 0.322 (0.02) |
| IL-12p70b | 5.1 (2.1–9.2) | 0.303 (0.004) | 9.2 (5.1–19.0) | |
| IL-13b | 4.2 (0.0–14.2) | 0.572 (0.001) | 22.7 (9.4–47.9) | 0.416 (0.005) |
| IL-15b | 1.5 (0.0–7.6) | 0.383 (0.002) | 27.9 (11.6–48.5) | |
| IL-1Rac | 50.1 (5.2–129.9) | 0.329 (0.003) | 5.1 (2.1–9.2) | |
| IL-1ab | 13.8 (3.3–39.3) | 0.530 (0.001) | 4.9 (3.3–17.7) | 0.477 (0.001) |
| IL-2c | 1.9 (0.0–7.2) | 0.412 (0.001) | 4.2 (0.0–14.2) | |
| IL-4c | 1.9 (0.0–15.0) | 0.609 (0.001) | 6.2 (0.6–18.2) | 0.446 (0.005) |
| IL-6b | 7.4 (2.0–14.2) | 1.5 (0.0–7.6) | 0.457 (0.001) | |
| IL-7b | 7.7 (2.6–14.7) | 0.370 (0.001) | 2.6 (0.0–8.9) | |
| TNF-βb | 4.2 (0.0–11.7) | 0.395 (0.001) | 50.1 (5.2–129.9) | |
The biomarkers that correlated significantly with sLRP1 at both study visits are in bold.
↵a Mediators having both pro- and antiinflammatory actions.
↵b Proinflammatory mediator.
↵c Antiinflammatory mediator. IFN: interferon; IL: interleukin; sLRP1: soluble low-density lipoprotein receptor-related protein 1; TNF: tumor necrosis factor.